Kulka Sales and Profit to Hit Record Highs in 2022

Slovenian pharmaceutical company Krka posted record sales and profits last year. Revenue increased 10% to €1.7 billion, and net profit rose 17% to €361 million, according to unaudited results the company released on Jan. 26.

Krka saw sales growth across all product and service segments in most of its key markets.

Sales in Eastern Europe increased by 14% to €623 million, in Central Europe by 4% to €364 million, and in Western and South Eastern Europe by 7% to €327 million and €225 million respectively In euros, the international market was up 23% to 66 million euros.

In Slovenia, the Group sold €103 million worth of products and services last year, an increase of 11% from 2021. Most of the revenue (60.5 million euros) came from product sales, with spa and tourist services contributing 42.6 euros to him. a million.

The group sold €1.4 billion worth of prescription drugs worldwide last year, a 7% increase year-on-year. Sales increased in all regions, with the Czech Republic, Germany and Russia leading the growth of their individual markets. Cardiovascular, central nervous system and gastrointestinal drugs remained at the top of the list of prescription drugs sold.

“With a good business model and continuous adaptations in different areas of our business, we were able to meet the challenges of last year,” CEO Jože Colarič told reporters at Novo Mesto’s headquarters.

The company has registered 11 new products and completed 490 registration procedures.

Investment expenditure reached €106 million and is expected to rise to €130 million in 2023.

Colarič pointed to a high-tech investment worth €39.2 million in Notol 2. This completes the investment totaling €259 million in this Novo Mesto-based facility dedicated to the production of solid pharmaceutical products.

A further €26 million will be invested in Notol 2 this year, and Krka wants to double its production capacity for animal products to ensure long-term production of high volumes of sterile products. The amount of investment he is estimated at 29 million euros.

The company will begin construction of a €163 million plant in Krško this year for the development and production of active pharmaceutical ingredients.

Planned investments abroad include a €3.5 million upgrade of the production capacity for solid dosage animal products at the production and distribution center in Yastrbarsko, Croatia. Ningbo Kurka Menovo joint venture will continue to source production and quality control equipment in China.

The Group plans a turnover of €1,755 million and a net profit of around €300 million this year.